| 教員紹介トップページへ | 三重大学トップページへ |
| 職名 | 助教 | ||||||||||||||||
| 氏名 | かげやま たくみ 景山 拓海 |
||||||||||||||||
| 生年月 | 1987.07 | ||||||||||||||||
|
|||||||||||||||||
| TEL | |||||||||||||||||
| FAX | |||||||||||||||||
| kagetaku@med. (末尾に mie-u.ac.jp を補ってください) | |||||||||||||||||
| ｒｅｓｅａｒｃｈｍａｐ | R000095625 | ||||||||||||||||
| 三重大学全学SEEDS集 | |||||||||||||||||
| 個人のホームページ | https://researchmap.jp/kagetaku | ||||||||||||||||
| 学歴 | 三重大学大学院医学系研究科生命医科学専攻 博士課程・博士後期課程 (2021年04月01日～2025年03月31日) 卒業・修了
|
||||||||||||||||
| 学位 | 2025.12 医学博士 三重大学
|
||||||||||||||||
| 所属学会 | 日本泌尿器科学会 日本癌治療学会 日本泌尿器内視鏡学会 日本泌尿器腫瘍学会 日本癌学会 日本旅行医学会 | ||||||||||||||||
| 社会活動 | |||||||||||||||||
| 職歴 | 2013.04～2015.03 三重県厚生連鈴鹿中央総合病院 初期臨床研修医
2015.04～2017.03 愛知県がんセンター中央病院 泌尿器科 レジデント 2017.04～2018.10 三重大学医学部附属病院 腎泌尿器外科 医員 2018.11～2021.03 三重県厚生連 鈴鹿中央総合病院 泌尿器科 医員 2025.04～ 三重大学医学部附属病院 腎泌尿器外科 助教 |
||||||||||||||||
| 学術（芸術）賞 | |||||||||||||||||
| 専門分野 | 前立腺癌、癌微小環境 | ||||||||||||||||
| 現在の研究課題 | |||||||||||||||||
| 担当科目 | |||||||||||||||||
| 主な業績等 | Review of Bioptic Gleason Scores by Central Pathologist Modifies the Risk Classification in Prostate Cancer. 2015 Urologia internationalis 95 452-6
Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level 竕･ 20 ng/dl. 2016.02 Current urology 9 31-5 High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes. 2016.07 Journal of cancer research and clinical oncology 142 1609-19 [A Case of Intrascrotal Liposarcoma]. 2016.09 Hinyokika kiyo. Acta urologica Japonica 62 495-500 Very high-risk prostate cancer: stratification by outcomes of radiotherapy and long-term androgen deprivation therapy. 2017.06 Asia-Pacific journal of clinical oncology 13 145-151 [LEIOMYOSARCOMA ARISING FROM THE RENAL VEIN]. 2019 Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 110 244-248 The GP Score, a Simplified Formula (Bioptic Gleason Score Times Prostate Specific Antigen) as a Predictor for Biochemical Failure after Prostatectomy in Prostate Cancer. 2019.09 Current urology 13 25-30 Succinate dehydrogenase B-deficient renal cell carcinoma with a germline variant in a Japanese patient: a case report. 2022.07 Human genome variation 9 25- Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration-resistant prostate cancer. 2022.11 IJU case reports 5 442-445 Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells. 2023.03 The Prostate 83 364-375 Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment. 2023.05 Cancers 15 Purine-Rich Element Binding Protein Alpha, a Nuclear Matrix Protein, Has a Role in Prostate Cancer Progression. 2024.06 International journal of molecular sciences 25 Narrative Review of Patient Cancer Tissue-Derived Zebrafish Xenograft Models for Evaluating Drug Sensitivity as an Avatar Model for Clinical Application. 2025.07 Cancer medicine 14 e70942- Endothelial-Mesenchymal Transition in Tumor Microenvironment Promotes Neuroendocrine Differentiation of Prostate Cancer. 2025.10 Cancer science 116 2712-2722 Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle-Invasive Bladder Cancer. 2025.10 Cancer science |
||||||||||||||||